Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0.26%1.13B | 15.25%977.54M | 13.36%4.38B | 13.95%1.25B | 19.63%1.16B | 9.06%1.12B | 10.36%848.19M | 26.60%3.87B | 12.70%1.09B | 28.70%972.58M |
Cost of revenue | 5.99%952.8M | 11.75%800.33M | 12.70%3.64B | 19.05%1.06B | 22.39%964.69M | 0.23%898.97M | 9.50%716.18M | 19.16%3.23B | 6.80%887M | 15.70%788.23M |
Gross profit | -22.60%174.33M | 34.25%177.22M | 16.70%746.28M | -7.93%190.29M | 7.82%198.77M | 68.21%225.22M | 15.25%132.01M | 84.81%639.48M | 47.70%206.68M | 147.72%184.36M |
Operating expense | -2.30%184.12M | 20.36%223.85M | 10.70%775.78M | 13.63%214.22M | 9.32%187.12M | 8.94%188.46M | 10.64%185.98M | 6.55%700.78M | 10.40%188.52M | 2.97%171.17M |
Staff costs | ---- | ---- | 3.92%385.18M | ---- | ---- | ---- | ---- | 1.88%370.66M | ---- | ---- |
Selling and administrative expenses | ---- | ---- | 10.22%149.43M | ---- | ---- | ---- | ---- | 22.75%135.58M | ---- | ---- |
-General and administrative expense | ---- | ---- | 10.22%149.43M | ---- | ---- | ---- | ---- | 22.75%135.58M | ---- | ---- |
Depreciation and amortization | ---- | ---- | -34.48%9.6M | ---- | ---- | ---- | ---- | -4.35%14.65M | ---- | ---- |
-Depreciation | ---- | ---- | -34.48%9.6M | ---- | ---- | ---- | ---- | -4.35%14.65M | ---- | ---- |
Other operating expenses | ---- | ---- | 28.73%231.57M | ---- | ---- | ---- | ---- | 7.00%179.89M | ---- | ---- |
Operating profit | -126.64%-9.79M | 13.60%-46.63M | 51.88%-29.5M | -231.82%-23.94M | -11.65%11.65M | 194.04%36.76M | -0.78%-53.98M | 80.33%-61.31M | 158.90%18.16M | 114.36%13.18M |
Net non-operating interest income (expenses) | -0.15%-3.26M | 7.56%-3.06M | -2.69%-13.2M | -2.28%-3.36M | -1.77%-3.28M | -1.98%-3.25M | -4.79%-3.31M | 0.62%-12.85M | -1.26%-3.29M | 0.89%-3.22M |
Non-operating interest income | 0.00%2K | 0.00%2K | 100.00%16K | 400.00%10K | 0.00%2K | 0.00%2K | 0.00%2K | 0.00%8K | 0.00%2K | 0.00%2K |
Non-operating interest expense | 0.15%3.26M | -7.56%3.06M | 2.75%13.22M | 2.52%3.37M | 1.77%3.28M | 1.97%3.25M | 4.78%3.31M | -0.62%12.86M | 1.26%3.29M | -0.89%3.23M |
Net investment income | 14.32%26.41M | 7.69%14K | 21.18%52.88M | 17.81%27.49M | -14.75%2.27M | 32.49%23.11M | -93.47%13K | 38.98%43.64M | 42.26%23.34M | 96.46%2.66M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -454.02%-16.4M | 0 | -1,817.65%-1.75M | -103.64%-4K | 5,837.50%459K | -2.96M | 753K | -89.58%102K | -91.89%110K | -117.02%-8K |
Less:Other special charges | ---- | ---- | 1,817.65%1.75M | 103.64%4K | ---459K | --2.96M | ---753K | 89.58%-102K | 91.89%-110K | ---- |
Other non-operating income (expenses) | 43.74%32.92M | 0.45%23.87M | -0.24%93.4M | 3.78%23.89M | -2.39%22.84M | -3.53%22.9M | 1.29%23.76M | 3.61%93.62M | 5.47%23.02M | 2.72%23.4M |
Income before tax | -60.96%29.89M | 21.21%-25.8M | 61.11%101.83M | -60.75%24.08M | -5.77%33.94M | 7,040.80%76.56M | 0.90%-32.75M | 131.30%63.2M | 1,013.76%61.34M | 150.81%36.02M |
Income tax | 309.25%14.38M | -217.76%-8.33M | 569.68%35.6M | 200.31%17.77M | -20.94%7.24M | 674.01%3.51M | 1,227.58%7.08M | -454.99%-7.58M | -3,417.79%-17.72M | 1,613.67%9.15M |
Net income | -78.78%15.5M | 56.14%-17.47M | -6.44%66.23M | -92.03%6.3M | -0.61%26.71M | 4,788.19%73.04M | -18.59%-39.82M | 134.69%70.78M | 1,489.62%79.05M | 137.62%26.87M |
Net income continuous operations | -78.77%15.5M | 56.14%-17.47M | -6.43%66.23M | -92.02%6.31M | -0.60%26.7M | 4,791.27%73.04M | -18.59%-39.82M | 134.69%70.78M | 1,489.62%79.05M | 137.62%26.87M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | -78.78%15.5M | 56.14%-17.47M | -6.44%66.23M | -92.03%6.3M | -0.61%26.71M | 4,788.19%73.04M | -18.59%-39.82M | 134.69%70.78M | 1,489.62%79.05M | 137.62%26.87M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -78.78%15.5M | 56.14%-17.47M | -6.44%66.23M | -92.03%6.3M | -0.61%26.71M | 4,788.19%73.04M | -18.59%-39.82M | 134.69%70.78M | 1,489.62%79.05M | 137.62%26.87M |
Gross dividend payment | ||||||||||
Basic earnings per share | -78.77%11.78 | 56.13%-13.27 | -6.43%50.31 | -92.02%4.79 | -0.59%20.29 | 4,801.69%55.48 | -18.58%-30.25 | 134.69%53.77 | 1,488.62%60.05 | 137.63%20.41 |
Diluted earnings per share | -78.77%11.7768 | 56.13%-13.27 | -6.43%50.31 | -92.03%4.7884 | -0.61%20.2848 | 4,788.04%55.48 | -18.58%-30.25 | 134.69%53.77 | 1,489.62%60.0468 | 137.62%20.4086 |
Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |